The Australian Competition and Consumer Commission's conditional approval of Internal Diagnostics' (ASX:IDX) proposed acquisition of Capitol Health (ASX:CAJ) will lead to an upside to shareholder returns, Jarden Research said in a Tuesday note.
The pending merger offers the company value-accretive opportunities, including increased scale, a broader referral base, telehealth integration, and improved billing accuracy to capture missed revenue from miscoding, the note said.
Post-merger, Jarden expects shareholder returns of about 28%.
It also expects the company to receive additional funding from the Australian Government National Lung Screening Program for scans for early detection of lung cancer.
The investment firm maintained Integral Diagnostics' buy rating but cut its target price to AU$3.68 from AU$3.72.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。